Immatics
Immatics is a Germany-based clinical-stage biopharmaceutical company that researches and develops T-cell immunotherapies for the treatment of cancer.
Business Model:
Revenue: $39.4M
Employees: 201-500
Industries / Tags:
Detailed Immatics Information
Geographic Data
Address: Paul-Ehrlich-Str. 15
City: Tuebingen
State: baden-württemberg
Zip: 72076
Country: DE
Financial Info
Stage:
post ipo equity
Raised Last:
$104M
Raised Total:$446M
Social
Metrics
2,196,740Website Global Rank
8,824Website Monthly Traffic
Twitter Followers
Description
Immatics is a Germany-based clinical-stage biopharmaceutical company that researches and develops T-cell immunotherapies for the treatment of cancer.
Contact Phone:
Contact Email:
Immatics went public on 7/2/2020 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
7/2/2020
Ticker Symbol:
IMTX
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
